Histórico Etiquetas: EMA

The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has announced that it is reassessing cases of heavy menstrual bleeding (heavy periods) and absence of menstruation (amenorrhea) after receiving the Covid-19 vaccines from Pfizer and Moderna. The Committee had previously discussed these menstruation problems and concluded at the time that the evidence «does not support a causal relationship ...

The Committee for Human Medicines (CHMP) of the European Medicines Agency (EMA) has recommended granting an extension for the vaccine against COVID-19 Spikevax (formerly known as COVID- 19 Vaccine Moderna) to include use in young people aged 12-17 years . The vaccine was already authorized in people over 18 years of age. The use of ...